MAYO CLINIC LABORATORIES

NEW TEST

Notification Date: December 28, 2021
Effective Date: January 04, 2021

RUNX1-RUNX1T1 Translocation (8;21), Minimal Residual Disease Monitoring, Quantitative, Varies

Test ID: T821Q

Useful for:
This test is a highly sensitive quantitative assay for the detection of translocation t(8;21)(q22;q22); RUNX1-RUNX1T1 gene fusion in acute myeloid leukemia (AML) patients, at the time of diagnosis as well as minimal residual disease (MRD) monitoring during the clinical and therapeutic course of these patients.

Methods:
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)

Reference Values:
An interpretive report will be provided

Specimen Requirements:
Submit only 1 of the following specimens:

Specimen Type: Blood
Container/Tube: Lavender top (EDTA) or yellow top (ACD-B)
Specimen Volume: 10 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
3. Label specimen as blood.

Specimen Type: Bone marrow aspirate
Container/Tube: Lavender top (EDTA) or yellow top (ACD-B)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix bone marrow.
2. Send bone marrow specimen in original tube. Do not aliquot.
3. Label specimen as bone marrow.

Specimen Stability Information:

Specimen Type	Temperature	Time
Varies	Refrigerated (preferred)	5 days
	Ambient	72 hours

Cautions:

The limit of detection for the T8;21 assay is 0.01%. Monitoring should be performed using the same method and laboratory for each subsequent specimen.

CPT Code:

81401-*RUNX1/RUNX1T1*

Day(s) Performed: Monday through Saturday **Report Available:** 4 to 8 days

Questions

Contact Connie Penz, Laboratory Technologist Resource Coordinator at 800-533-1710.